Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Mallinckrodt
Colorcon
Johnson and Johnson
Merck

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Litigation Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LLC (D.N.J. 2015)

See Plans and Pricing

« Back to Dashboard

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LLC (D.N.J. 2015)

Docket   Start Trial Date Filed 2015-11-30
Court District Court, D. New Jersey Date Terminated 2016-07-22
Cause 35:271 Patent Infringement Assigned To Stanley R. Chesler
Jury Demand None Referred To
Parties ACTAVIS ELIZABETH LLC; ACTAVIS LLC; ACTAVIS, INC.; ALLERGAN PLC; PROGENICS PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, INC.; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; WYETH LLC
Patents 8,247,425; 8,420,663; 8,552,025; 8,822,490; 9,180,125
Attorneys BRYAN C. DINER; ELVIN ESTEVES; ELVIN ESTEVES (Do not use or delete); J. BRUGH LOWER; JASON B. LATTIMORE; MICHAEL ANDREW HOLTMAN; WILLIAM P. DENI , JR.
Link to Docket External link to docket
Small Molecule Drugs cited in VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LLC (D.N.J. 2015)

Date Filed Document No. Description Snippet Link To Document
2016-02-18 7 United States Patent Nos. 8,247,425 (“the ’425 patent”); 8,420,663 (“the ’663 patent”); 8,552,025 (“…. 021964, the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and ’125 patent are listed in the FDA…expiration of the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and ’125 patent or such later date…expiration of the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and ’125 patent or such later date…expiration of the ’425 patent, ’663 patent, ’025 patent, ’490 patent, and ’125 patent; 9. declare External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Johnson and Johnson
Moodys
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.